S&P 500
7,757.17
+44.60
+0.58%
Dow
52,856.09
+360.21
+0.69%
Nasdaq
26,702.86
+278.04
+1.05%
NYSE Composite
24,253.12
+62.51
+0.26%
Russell 2000
2,781.02
+7.60
+0.27%
VIX
16.68
-0.63
-3.64%
OKUR · OnKure Therapeutics, Inc. Class A
NASDAQ NMS - GLOBAL MARKET - BOATS Real Time Price • USD
Onkure Therapeutics Inc (OKUR)
NASDAQ NMS - GLOBAL MARKET
Biotechnology
$2.31
-0.06
(-2.74%)
● At close: October 21 at 4:00:00 PM EDT
DAY'S RANGE
$2.31
$2.26
$2.35
52-WEEK RANGE
$2.31
$2.01
$5.38
What's happening
- OKUR is down 2.74% today, trading at $2.31. — Live quote
- Volume today (7,916) is well below its 3-month average of 292,170. (Finnhub fundamentals)
- Reports earnings on 2026-11-05, 14 days away. (Finnhub earnings calendar)
- Last quarter's EPS beat estimates: $-0.31 actual vs. $-0.55 estimated (+43.2%). (Finnhub earnings history)
Deterministic template sentences filled in from the same sourced figures shown elsewhere on this page -- not an AI-written summary, no live model call.
Key Statistics
Analyst Recommendations
Strong buy 4
Buy 6
Hold 2
Sell 0
Strong sell 0
Aggregate ratings for 2026-10-01 (12 analysts polled by Finnhub) — consensus count.
Performance Overview (Trailing returns vs S&P 500 benchmark)
YTD RETURN
OKUR
-18.62%
vs S&P 500
-31.40%
1-YEAR RETURN
OKUR
-19.45%
vs S&P 500
-34.02%
6-MONTH RETURN
OKUR
-49.46%
3-MONTH RETURN
OKUR
-43.41%
Earnings Trends (Quarterly EPS Actual vs Estimate)
2026-07-26 (Q2 2026)
$-0.31
Est. $-0.55
BEAT +43.2%
2026-04-26 (Q1 2026)
$-1.11
Est. $-0.76
MISS -46.6%
2026-01-26 (Q4 2025)
$-0.99
Est. $-1.18
BEAT +15.7%
2025-10-26 (Q3 2025)
$-1.09
Est. $-1.22
BEAT +10.8%
Valuation Measures & Ratios
Enterprise Value4-$73.4M
Forward P/E5—
PEG Ratio6—
Price / Sales (TTM1)—
Price / Book71.07
EV4 / Revenue—
EV4 / EBITDA—
Profit Margin—
Operating Margin—
Return on Equity (ROE8)-49.02%
Return on Assets (ROA9)-45.77%
Avg Volume (3M)292,170
Quarterly history (5 periods)
| Measure | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 |
|---|---|---|---|---|---|
| Market cap | $225.2M | $56.3M | — | $37.2M | $32.9M |
| P/E | -3.84 | -0.96 | — | -0.59 | -0.55 |
| Price/Book | 1.31 | 0.31 | — | 0.56 | 0.42 |
| ROE | -34.11% | -31.87% | — | -95.53% | -77.16% |
| ROA | -32.73% | -29.57% | — | -87.12% | -70.07% |
Trailing-twelve-month ratios computed from SEC EDGAR quarterly figures and historical daily close prices (Alpaca). Diluted shares are derived from Net income ÷ EPS (diluted) for each quarter, not separately reported. Forward P/E/PEG unavailable (no free data source).
Glossary — what these abbreviations mean
- 1. TTM
- Trailing twelve months — the sum of the last four reported quarters, not a calendar year or the single latest quarter.
- 2. EPS
- Earnings per share — net income divided by diluted shares outstanding.
- 3. Beta
- A stock's historical volatility relative to the overall market. Above 1 means it has moved more than the market; below 1, less.
- 4. EV (Enterprise Value)
- Market cap plus total debt minus cash — roughly what it would cost to buy the whole company, debt included.
- 5. Forward P/E
- Price divided by analysts' estimated earnings for the next 12 months, instead of trailing actual earnings.
- 6. PEG Ratio
- P/E divided by expected earnings growth rate. A lower number can indicate a stock is cheap relative to how fast it's expected to grow.
- 7. Price / Book
- Share price divided by book value (assets minus liabilities) per share.
- 8. ROE
- Return on equity — net income divided by shareholders' equity, a measure of how efficiently a company turns equity into profit.
- 9. ROA
- Return on assets — net income divided by total assets, a measure of how efficiently a company turns assets into profit.
- 10. MRQ
- Most recent quarter — the single latest reported period, as opposed to TTM. The Financials section's "Quarterly" view below shows MRQ-style figures.
- 11. YoY
- Year over year — percent change versus the same period one year earlier, used for growth figures like those on Compare cards and the Screener.
Short Interest
Shares Short1,223,923
Change from Prior Settlement-11.00%
% of Float—
Days to Cover (Short Ratio)4.76
Source: FINRA Rule 4560 consolidated short interest, settlement date 2026-09-30. Reported bi-monthly with a reporting lag — not real-time.
Quotes and the 1-day extended-hours chart: Yahoo Finance. Longer historical charts: Alpaca (IEX feed) — real-time but IEX-only volume (~2.5% of consolidated market volume). Fundamentals + earnings: Finnhub.
Price history
Events
Drag horizontally to zoom into a section; use Reset view to restore all observations.
Technical signal summary
Calculating from the latest year of daily price history…
Show Technical Analysis Breakdown ▾ 10 Indicators
Not investment advice — read several signals together.
Indicators None active
Loading chart…
History limited by data provider; markers are heuristics, not signals.
Peer and sector context
No reviewed peer group is available for this symbol.
Balanced evidence
A deterministic summary of sourced facts—not an AI verdict.
Potential strengths
- Latest SEC filing is Form 4, filed 2026-09-23; review it for current changes and risks. SEC EDGAR ↗
Potential concerns
- Trailing 52-week price return is -19.5%. Finnhub market metrics ↗
Rule-based facts only; absence from either side is not evidence, and this is not a recommendation.
More on OKUR
No accessible free API for these — links go to the source directly.
Financials
Fundamental trends
Visualized from the same SEC figures in the tables below.
Income statement
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Operating income | -$16.9M | -$15.6M | — | -$15.5M | -$16.3M | -$17.0M | — | -$11.5M |
| Net income | -$15.3M | -$15.2M | -$13.5M | -$14.7M | -$15.4M | -$15.9M | -$17.4M | -$11.6M |
| EPS (diluted) | $-0.31 | $-1.11 | — | $-1.09 | $-1.14 | $-1.19 | — | $-36.55 |
| EPS (basic) | $-0.31 | $-1.11 | — | $-1.09 | $-1.14 | $-1.19 | — | $-36.55 |
Balance sheet
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Total assets | $179.4M | $198.7M | $62.1M | $72.8M | $86.1M | $99.9M | $114.9M | $77.6M |
| Total liabilities | $7.2M | $14.3M | $5.9M | $6.4M | $7.9M | $9.2M | $11.1M | $3.6M |
| Stockholders' equity | $172.1M | $184.4M | $56.2M | $66.4M | $78.2M | $90.6M | $103.8M | -$135.1M |
| Total current assets | $177.7M | $197.5M | $60.8M | $71.5M | $84.6M | $98.2M | $113.0M | $77.0M |
| Total current liabilities | $6.6M | $14.3M | $5.9M | $6.2M | $7.6M | $8.8M | $10.5M | $3.2M |
| Cash & equivalents | $166.5M | $192.1M | $59.0M | $70.3M | $83.4M | $96.7M | $110.8M | $60.7M |
| Marketable securities (current) | — | — | — | — | — | — | — | $16.0M |
| Property, plant & equipment | $435.0K | $519.0K | $618.0K | $720.0K | $821.0K | $925.0K | $1.0M | $59.0K |
| Other non-current assets | $401.0K | $405.0K | $273.0K | $104.0K | $116.0K | $109.0K | $109.0K | $147.0K |
| Accounts payable | $2.0M | $11.0M | $1.4M | $1.3M | $2.4M | $2.3M | $3.0M | $237.0K |
| Accrued liabilities | — | — | — | — | $4.7M | $5.9M | $7.0M | $725.0K |
| Other non-current liabilities | $12.0K | $12.0K | $12.0K | $40.0K | $40.0K | $40.0K | — | — |
| Common stock & paid-in capital | — | — | — | — | — | — | — | $0 |
| Retained earnings | -$244.7M | -$229.4M | -$214.2M | -$200.7M | -$186.0M | -$170.6M | -$154.7M | -$236.0M |
| Accumulated other comprehensive income (loss) | -$13.0K | — | $0 | — | — | — | — | $2.0K |
Cash flow
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$10.4M | -$12.9M | -$11.5M | -$13.0M | -$13.3M | -$14.0M | -$23.4M | -$10.7M |
| Investing cash flow | -$9.9M | -$5.0K | -$9.0K | -$6.0K | -$13.0K | -$18.0K | $15.9M | -$18.0K |
| Financing cash flow | -$5.4M | $146.0M | $240.0K | $0 | $0 | -$77.0K | $110.2M | $5.0K |
| Free cash flow | -$10.4M | -$12.9M | -$11.5M | -$13.0M | -$13.3M | -$14.0M | -$23.4M | -$10.7M |
| Capital expenditures | $3.0K | $5.0K | $9.0K | $6.0K | $13.0K | $18.0K | $15.0K | $18.0K |
| Depreciation & amortization | $87.0K | $104.0K | $212.0K | $108.0K | $117.0K | $118.0K | $345.0K | $114.0K |
| Share-based compensation | $3.0M | $2.8M | $3.0M | $3.0M | $2.9M | $2.7M | $2.5M | $77.0K |
| Purchases of investments | $9.9M | — | — | — | — | — | — | — |
| Sales/maturities of investments | — | — | $15.9M | — | — | — | -$113.1M | $25.0M |
| Share repurchases | — | — | — | — | — | — | — | — |
Income statement
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Revenue | — | $0 | — | — | — |
| Operating income | -$63.0M | -$54.4M | -$36.9M | -$53.8M | -$39.8M |
| Net income | -$59.5M | -$52.7M | -$35.3M | -$52.0M | -$39.8M |
| EPS (diluted) | $-4.40 | $-15.28 | $-124.41 | $-2.12 | $-2.19 |
| EPS (basic) | $-4.40 | $-15.28 | $-124.41 | $-2.12 | $-2.19 |
Balance sheet
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Total assets | $62.1M | $114.9M | $35.7M | $108.2M | $154.0M |
| Total liabilities | $5.9M | $11.1M | $7.8M | $8.2M | $6.8M |
| Stockholders' equity | $56.2M | $103.8M | -$101.8M | -$54.4M | $147.2M |
| Total current assets | $60.8M | $113.0M | $33.8M | $106.4M | $153.7M |
| Total current liabilities | $5.9M | $10.5M | $7.3M | $7.1M | $6.2M |
| Cash & equivalents | $59.0M | $110.8M | $29.9M | $19.9M | $124.7M |
| Marketable securities (current) | — | — | $75.3M | $81.2M | $23.0M |
| Property, plant & equipment | $618.0K | $1.0M | $1.4M | $453.0K | $212.0K |
| Other non-current assets | $273.0K | $109.0K | $58.0K | $84.0K | $78.0K |
| Accounts payable | $1.4M | $3.0M | $3.4M | $1.9M | $2.0M |
| Accrued liabilities | — | $7.0M | $3.7M | $4.8M | $4.2M |
| Other non-current liabilities | $12.0K | — | — | — | $167.0K |
| Common stock & paid-in capital | — | — | $3.0K | $3.0K | $3.0K |
| Retained earnings | -$214.2M | -$154.7M | -$102.1M | -$136.7M | -$84.7M |
| Accumulated other comprehensive income (loss) | — | — | $8.0K | -$43.0K | $34.0K |
Cash flow
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Operating cash flow | -$51.8M | -$51.1M | -$34.5M | -$47.4M | -$38.0M |
| Investing cash flow | -$46.0K | $15.9M | -$246.0K | -$57.8M | -$23.4M |
| Financing cash flow | $163.0K | $116.1M | $53.1M | $471.0K | $132.4M |
| Free cash flow | -$51.9M | -$51.2M | -$34.8M | -$47.7M | -$38.2M |
| Capital expenditures | $46.0K | $52.0K | $246.0K | $346.0K | $198.0K |
| Depreciation & amortization | $447.0K | $459.0K | $417.0K | $88.0K | $50.0K |
| Share-based compensation | $11.6M | $4.5M | $199.0K | $4.3M | $3.9M |
| Sales/maturities of investments | $15.9M | $15.9M | $242.0M | $44.1M | $8.2M |
| Share repurchases | — | — | $4.4M | — | — |
Source: SEC EDGAR XBRL filings (10-Q/10-K), as originally tagged by the company. Quarterly cash flow is reconstructed by de-cumulating fiscal-year-to-date figures (how cash flow is tagged in 10-Qs); other quarterly lines are reported directly.
Institutional holders
SEC Form 13F filers holding OKUR as of the latest reported quarter. 13F only covers investment managers with $100M+ in assets — this is not a complete ownership picture, and does not include insiders (see Recent SEC filings below) or non-13F-eligible holders.
Institutional ownership is not available for this symbol right now.
Insider activity
Directors, officers, and 10%+ owners' reported transactions from SEC Form 4. A filing reports a transaction; it does not by itself explain why it happened.
Insider activity is not available for this symbol right now.
Recent SEC filings
Official company reports and insider transaction filings. Form 4 reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR submissions · updated 2026-10-22 03:01 UTC
| Filed | Form | Report period | Official filing |
|---|---|---|---|
| 2026-09-23 | 4 | 2026-09-21 | View on SEC.gov → |
| 2026-09-23 | 4 | 2026-09-21 | View on SEC.gov → |
| 2026-08-13 | 8-K | 2026-08-07 | View on SEC.gov → |
| 2026-08-11 | 4 | 2026-08-07 | View on SEC.gov → |
| 2026-08-11 | 4 | 2026-08-07 | View on SEC.gov → |
| 2026-08-11 | 4 | 2026-08-07 | View on SEC.gov → |
| 2026-08-11 | 4 | 2026-08-07 | View on SEC.gov → |
| 2026-08-11 | 4 | 2026-08-07 | View on SEC.gov → |
| 2026-08-11 | 4 | 2026-08-07 | View on SEC.gov → |
| 2026-08-11 | 4 | 2026-08-07 | View on SEC.gov → |
| 2026-08-11 | 4 | 2026-08-07 | View on SEC.gov → |
| 2026-08-11 | 4 | 2026-08-07 | View on SEC.gov → |
Recent news
Headlines about OKUR (OnKure Therapeutics, Inc. Class A). Links open the publisher — we don’t host full articles.
-
OnKure Therapeutics to Participate in the Morgan Stanley Global Healthcare Conference
Yahoo Finance · 2026-08-31 -
OnKure Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Highlights
Yahoo Finance · 2026-08-04 -
OnKure Therapeutics Spotlights Allosteric PI3Kα Drugs as 2027 IND Targets Near
Yahoo Finance · 2026-07-15 -
OnKure Therapeutics to Host Virtual KOL Event to Discuss PI3Kα Inhibitor Medicines: Selectivity Matters & Pan-Mutant Allosteric Inhibition Delivers, on July 15, 2026
Yahoo Finance · 2026-07-02 -
OnKure Therapeutics GAAP EPS of -$1.11 misses by $0.37
Seeking Alpha · 2026-05-05 -
OnKure Therapeutics Reports First Quarter 2026 Financial Results
Yahoo Finance · 2026-05-05 -
TMO Q1 Earnings Preview: Will Life Sciences Solutions Lead Results?
Yahoo Finance · 2026-04-16 -
OnKure Therapeutics Announces Oversubscribed $150 Million Private Placement to Advance Next-Generation PI3Kα Pan-Mutant Selective Inhibitor Candidates in Breast Cancer and Vascular Anomalies
Yahoo Finance · 2026-03-27
No headlines in this category right now — try “All”.